Nancy Grubb, MD
Family Medicine · Puyallup, WANPI 1538101795
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $841 and has fallen 84.5% since, to $130 in 2022.
Across 82 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$180
- Pfizer$159
- Lilly USA, LLC$143
- Novo Nordisk$119
- Bayer$58
- Ironshore Pharmaceuticals Inc.$58
- plus $550 from 20 others
What the payments were for
- Food & beverage$1,22897%
- Education$383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $180 |
| Pfizer | 14 | $159 |
| Lilly USA, LLC | 11 | $143 |
| Novo Nordisk | 7 | $119 |
| Bayer | 3 | $58 |
| Ironshore Pharmaceuticals Inc. | 3 | $58 |
| Amgen | 2 | $56 |
| GSK | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Genentech USA, Inc. | 2 | $43 |
| AMAG Pharmaceuticals, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Alfasigma USA, Inc. | 1 | $30 |
| AstraZeneca | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Upsher-smith Laboratories LLC | 2 | $22 |
| AbbVie | 1 | $22 |
| Therapeuticsmd, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Kaleo, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Qiagen, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $11 |
| Vanda Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,266 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Puyallup
- William KriegsmanPuyallup$41K
- Daria SciarronePuyallup$26K
- Katherine BrewerPuyallup$17K
- Eugenia GurayPuyallup$10K
- John DanielPuyallup$9K
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.